gatifloxacin has been researched along with Chemotherapy-Induced Acral Erythema in 1 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 5.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 1.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noguchi, Y | 1 |
| Mitani, T | 1 |
| Kawara, H | 1 |
| Tokuyama, Y | 1 |
| Tamura, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 1 |
1 other study available for gatifloxacin and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine | 2015 |